LU91867I9 - - Google Patents
Info
- Publication number
- LU91867I9 LU91867I9 LU91867C LU91867C LU91867I9 LU 91867 I9 LU91867 I9 LU 91867I9 LU 91867 C LU91867 C LU 91867C LU 91867 C LU91867 C LU 91867C LU 91867 I9 LU91867 I9 LU 91867I9
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46121503P | 2003-04-08 | 2003-04-08 | |
| PCT/EP2004/003656 WO2004089341A1 (en) | 2003-04-08 | 2004-04-06 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LU91867I2 LU91867I2 (fr) | 2011-11-08 |
| LU91867I9 true LU91867I9 (Direct) | 2019-01-03 |
Family
ID=32326722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91867C LU91867I2 (fr) | 2003-04-08 | 2011-09-08 | Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®) |
Country Status (41)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1773307E (pt) * | 2004-07-30 | 2015-01-14 | Novartis Ag | Formulações de compostos à base de 2-amino-1,3- propanodiol |
| CN1891212B (zh) * | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
| AU2006289100B2 (en) * | 2005-09-09 | 2010-07-22 | Novartis Ag | Treatment of autoimmune diseases |
| EP1948678B1 (en) | 2005-11-09 | 2013-05-01 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| ES2415632T3 (es) | 2006-06-19 | 2013-07-26 | Onyx Therapeutics, Inc. | Epoxicetonas peptídicas para la inhibición del proteosoma |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| KR20090057399A (ko) * | 2006-09-26 | 2009-06-05 | 노파르티스 아게 | Ｓ１ｐ 조정제를 포함하는 제약 조성물 |
| AU2011235934A1 (en) * | 2006-09-26 | 2011-11-03 | Novartis Ag | Pharmaceutical compositions comprising an S1P modulator |
| EP1923054A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| CA2680039C (en) | 2007-03-29 | 2015-05-26 | Daiichi Sankyo Company, Limited | Pharmaceutical composition comprising edoxaban, an anticoagulant |
| EP2612865A3 (en) | 2007-10-04 | 2014-03-19 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| AU2012216630B2 (en) * | 2007-10-12 | 2015-01-22 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators |
| EP3120833A1 (en) * | 2007-10-12 | 2017-01-25 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| JP5534645B2 (ja) * | 2008-01-11 | 2014-07-02 | 日医工株式会社 | 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤 |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| KR101653071B1 (ko) | 2008-03-17 | 2016-08-31 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| WO2009152922A1 (de) * | 2008-06-20 | 2009-12-23 | Merck Patent Gmbh | Direkt verpressbare und schnell zerfallende tablettenmatirx |
| EP2303250A1 (en) | 2008-06-20 | 2011-04-06 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
| CA2735037C (en) * | 2008-09-04 | 2016-07-12 | Cargill Incorporated | Tabletting of erythritol |
| CN102256616A (zh) | 2008-10-21 | 2011-11-23 | 欧尼斯治疗公司 | 与肽环氧酮的联合疗法 |
| AU2013100531B4 (en) * | 2008-11-11 | 2013-11-28 | Novartis Ag | Crystalline forms of fingolimod HCL |
| CN102256933A (zh) | 2008-11-11 | 2011-11-23 | 诺瓦提斯公司 | 芬戈莫德的盐 |
| AU2009315736B2 (en) * | 2008-11-11 | 2013-08-29 | Novartis Ag | Crystalline forms of fingolimod HCL |
| CA2747427C (en) | 2008-12-17 | 2015-10-13 | Daiichi Sankyo Company, Limited | Method for producing diamine derivative |
| WO2010082531A1 (ja) | 2009-01-13 | 2010-07-22 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
| CN102348688B (zh) | 2009-03-10 | 2014-07-09 | 第一三共株式会社 | 用于制备二胺衍生物的方法 |
| JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| MY155256A (en) * | 2009-06-18 | 2015-09-30 | Daiichi Sankyo Co Ltd | Pharmaceutical composition having improved solubility |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
| ES2601884T3 (es) | 2010-03-19 | 2017-02-16 | Daiichi Sankyo Company, Limited | Procedimiento para mejorar la capacidad de disolución de un anticoagulante |
| ES2560955T3 (es) | 2010-03-19 | 2016-02-23 | Daiichi Sankyo Company, Limited | Cristal de derivado de diamina y procedimiento de producción del mismo |
| US20130095177A1 (en) * | 2010-04-22 | 2013-04-18 | Ratiopharm Gmbh | Method of preparing an oral dosage form comprising fingolimod |
| EP2589590B1 (en) | 2010-07-02 | 2016-12-28 | Daiichi Sankyo Company, Limited | Process for preparation of optically active diamine derivative salt |
| US9266816B2 (en) | 2010-11-25 | 2016-02-23 | Shilpa Medicare Limited | Fingolimod polymorphs and their processes |
| HRP20191842T1 (hr) | 2011-01-07 | 2019-12-27 | Novartis Ag | Formulacije imunosupresiva |
| WO2012100043A2 (en) | 2011-01-19 | 2012-07-26 | Pathlogica LLC | Controlled release oral pharmaceutical dosage forms comprising mgbg |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| WO2013019872A1 (en) | 2011-08-01 | 2013-02-07 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions comprising fingolimod |
| JPWO2013022059A1 (ja) | 2011-08-10 | 2015-03-05 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
| WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| ES2859553T3 (es) | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| WO2014175287A1 (ja) * | 2013-04-26 | 2014-10-30 | 国立大学法人 京都大学 | 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物 |
| WO2013190151A1 (en) * | 2013-05-13 | 2013-12-27 | Synthon B.V. | Pharmaceutical composition comprising fingolimod |
| CA2920758A1 (en) * | 2013-07-29 | 2015-02-05 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| RU2530626C1 (ru) * | 2013-10-21 | 2014-10-10 | Ооо "Валента-Интеллект" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| CN106794159A (zh) * | 2014-08-22 | 2017-05-31 | 广东东阳光药业有限公司 | 一种芬戈莫德固体组合物及其制备方法 |
| WO2016042493A1 (en) * | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| CN107530301A (zh) * | 2015-01-20 | 2018-01-02 | 汉达医药有限责任公司 | 稳定的固体芬戈莫德剂型 |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| WO2016135644A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| RU2577230C1 (ru) * | 2015-04-09 | 2016-03-10 | Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" | Способ получения капсул финголимода гидрохлорида |
| US9690975B2 (en) | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| WO2018178744A1 (en) | 2017-03-29 | 2018-10-04 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| GR1009654B (el) | 2018-08-31 | 2019-11-18 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| DE102018217334A1 (de) | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
| US11298412B2 (en) | 2020-07-16 | 2022-04-12 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection |
| JP2024506825A (ja) * | 2021-01-28 | 2024-02-15 | プリオセラ エスエーエス | Ｓ１ｐ受容体調節剤による処置の方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| US4110332A (en) * | 1977-05-05 | 1978-08-29 | Chevron Research Company | 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones |
| US4559153A (en) | 1983-10-25 | 1985-12-17 | Phillips Petroleum Company | Metal working lubricant |
| US5112616A (en) | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| JP2841857B2 (ja) * | 1990-11-29 | 1998-12-24 | 田辺製薬株式会社 | 長期間安定な経口用医薬製剤 |
| ES2126658T3 (es) * | 1992-10-21 | 1999-04-01 | Yoshitomi Pharmaceutical | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. |
| DE69524962D1 (de) | 1994-08-22 | 2002-02-14 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| ATE279185T1 (de) | 1995-12-28 | 2004-10-15 | Mitsubishi Pharma Corp | 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden |
| US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| JP2002241272A (ja) | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| DK0990440T3 (da) * | 1997-02-27 | 2009-02-23 | Novartis Ag | Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid |
| PT1002792E (pt) * | 1997-04-04 | 2004-12-31 | Mitsubishi Pharma Corp | Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP3545595B2 (ja) | 1998-04-01 | 2004-07-21 | 花王株式会社 | スフィンゴ糖脂質の製造法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| EP1195165A4 (en) * | 1999-07-12 | 2005-08-10 | Ono Pharmaceutical Co | FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS |
| NZ533997A (en) | 2000-07-13 | 2005-11-25 | Sankyo Co | Amino alcohol derivatives |
| AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| US6953332B1 (en) | 2000-11-28 | 2005-10-11 | St. Jude Medical, Inc. | Mandrel for use in forming valved prostheses having polymer leaflets by dip coating |
| PL367348A1 (en) | 2001-03-26 | 2005-02-21 | Novartis Ag | 2-amino-propanol derivatives |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
| JP4217620B2 (ja) | 2001-09-27 | 2009-02-04 | 杏林製薬株式会社 | ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤 |
| EP1431275B1 (en) | 2001-09-27 | 2010-04-07 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| CA2472715A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| EP1513522A2 (en) | 2002-01-18 | 2005-03-16 | Sri International | Methods of treating conditions associated with an edg receptor |
| EP1469863A2 (en) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| EP1772145B1 (en) * | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
-
2004
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en not_active Ceased
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
-
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
-
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
-
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
-
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
-
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I1/el unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
-
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
-
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
-
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
-
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
-
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
-
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
-
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
-
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned